The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Open accessAbstract
Background: A National human papilloma virus (HPV) Vaccination Programme for the prevention of HPV infection and associated disease using the quadrivalent HPV vaccine (4vHPV) has been funded and implemented in Australia since 2007, initially for girls only and extended to boys in 2013, with uptake rates among the highest observed worldwide. Aim: We report on the impact of this national programme on HPV prevalence and associated disease burden and estimate the potential impact of adopting a nonavalent HPV (9vHPV) vaccine. Methods: We performed a non-systematic literature review of studies measuring the burden of HPV-associated disease and infection in Australia before and after introduction of HPV vaccination. We also included key national reports with estimates of HPV-related disease burden. Results: Substantial declines in high-grade cervical disease and genital warts among vaccine-eligible women have been observed. Reductions in genital warts incidence and HPV prevalence among heterosexual men of similar age were observed before introduction of the male vaccination programme, indicating a substantial herd effect. 9vHPV vaccine is expected to prevent up to 90% of cervical and 96% of anal cancers. Of an estimated 1,544 HPV-associated cancers in 2012, 1,242 would have been preventable by the 4vHPV vaccine and an additional 187 anogenital cancers by the 9vHPV vaccine. Conclusions: Vaccination using 4vHPV vaccine has had a large demonstrable impact on HPV-related disease in Australia. A switch to 9vHPV could further reduce the HPV-associated cancer burden. With continued high coverage among both males and females, elimination of vaccine-type HPV disease seems achievable in Australia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal Cancers
Chaturvedi, A. K., Anderson, W. F., Lortet-Tieulent, J., Curado, M. P., Ferlay, J., Franceschi, S., Rosenberg, P. S., Bray, F., & Gillison, M. L. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3870 · Cited by 1,293
De Vuyst, H., Clifford, G. M., Nascimento, M. C., Madeleine, M. M., & Franceschi, S. (2009) · International Journal of Cancer · doi:10.1002/ijc.24116 · Cited by 966
Machalek, D. A., Poynten, M., Jin, F., Fairley, C. K., Farnsworth, A., Garland, S. M., Hillman, R. J., Petoumenos, K., Roberts, J., Tabrizi, S. N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70080-3 · Cited by 963
US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines
Saraiya, M., Unger, E. R., Thompson, T. D., Lynch, C. F., Hernandez, B. Y., Lyu, C. W., Steinau, M., Watson, M., Wilkinson, E. J., Hopenhayn, C., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv086 · Cited by 761
Drolet, M., Bénard, É., Boily, M.-C., Ali, H., Baandrup, L., Bauer, H., Beddows, S., Brisson, J., Brotherton, J. M. L., Cummings, T., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)71073-4 · Cited by 642
Self-citationAli, H., Donovan, B., Wand, H., Read, T. R. H., Regan, D. G., Grulich, A. E., Fairley, C. K., & Guy, R. J. (2013) · BMJ · doi:10.1136/bmj.f2032 · Cited by 426
Self-citationDonovan, B., Franklin, N., Guy, R., Grulich, A. E., Regan, D. G., Ali, H., Wand, H., & Fairley, C. K. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70225-5 · Cited by 380
Self-citationBrisson, M., Bénard, É., Drolet, M., Bogaards, J. A., Baussano, I., Vänskä, S., Jit, M., Boily, M.-C., Smith, M. A., Berkhof, J., et al. (2016) · The Lancet Public Health · doi:10.1016/s2468-2667(16)30001-9 · Cited by 307
Kreimer, A. R., Struyf, F., Del Rosario-Raymundo, M. R., Hildesheim, A., Skinner, S. R., Wacholder, S., Garland, S. M., Herrero, R., David, M.-P., & Wheeler, C. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00047-9 · Cited by 306
Cited by
Kombe Kombe, A. J., Li, B., Zahid, A., Mengist, H. M., Bounda, G.-A., Zhou, Y., & Jin, T. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2020.552028 · Cited by 646
Next-generation vaccine platforms for COVID-19
van Riel, D., & de Wit, E. (2020) · Nature Materials · doi:10.1038/s41563-020-0746-0 · Cited by 374
Çelik, P., & İncesoy Özdemir, S. (2021) · Journal of Pediatric Infection · doi:10.5578/ced.202119803 · Cited by 3
Metadata
- Authors
- Patel, C., Brotherton, J. M., Pillsbury, A., Jayasinghe, S., Donovan, B., Macartney, K., & Marshall, H.
- Venue
- Eurosurveillance
- Published
- 2018-10-11
- Volume
- 23
- Issue
- 41
- ISSN
- 1025-496X (ISSN-L)
- 1560-7917
- OpenAlex
- W2896597103
- Cited by
- 317
- References
- 55
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? https://app.cochat.ai/papers/10.2807/1560-7917.es.2018.23.41.1700737
- The paper
- Patel, C., Brotherton, J. M., Pillsbury, A., Jayasinghe, S., Donovan, B., Macartney, K., & Marshall, H. (2018). The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Eurosurveillance. https://doi.org/10.2807/1560-7917.es.2018.23.41.1700737
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.